The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
UPPING THE SPREAD 18% ??????
Homer, 30p is certainly a possibility and will make newbies buying at these low bargain prices very happy. Don't forget that N4P has been over 30p in the past. I'm hoping for a Tempest Therapeutics style rise for N4P. They went up x39 last year in a couple of trading days. See Bloomberg headline, below:
"Near-4,000% Surge Catapults One Tiny Biotech Firm to Record Week. Tempest adds more than $120 million in market value in October from gain"
GO NAP GO LOL
I hope it's not another AIM company that gets taken over very cheaply. Ridiculous price.
268 MIL SHARES NOT MANY IF IT STARTS TO RE RATE
If it went 220% i think it would still be worth almost fck all!
Well this is a nice surprise
It's 1.30 to buy. Personally feel the shackles have come off from the last placement.
Wake me up at 30p.
1.19/1.24
atm
TINY BUYS AND THE PRICE FLYING
SOME THING FISHY
1.14/1.19
atm
AND IM IN CREDIT WHOOP
Possible leak?
News due on several fronts.
1.11.1.14
atm
Volume is up considerably, this can move quickly as LTH’s know.
She’s gonna blow …
Nuvecs’s use as an Oral Delivery Technology.
“Further news on this will be announced in The New Year”
Speculation or something more?
It's a sector thing today, AGL has done over 100% today and people were scrambling to buy in all bombed out bio/pharma stocks. Certainly a lot of them are near all time lows. Big 2 mil+ sale at the close, it could be a buy that started things but even if it's a sale it's a big seller out so win win for tomorrrow
Personally it may be people realising what a bargain N4P is or they have wind of some news. That 900+k late reported buy is a clue along with the fact you can sell in large amounts if you wish.
Does anyone know why we are up today, has there been any news?
Yes I think as LTI's all see the huge potential but so often it’s hyped up by disreputable companies/CEOs who pump up the share prices with nice RNSs then deliver very little and just raise more funds. I was a private company CEO and my investors would have fired me for that many times over!
This was undervalued when it was 12p, the market hasn’t recognised the fact that this isn’t a drug that’s being developed, it’s a vehicle in which to transport endless drugs, vaccines, genes etc.
What I like here as an investor, is I believe we will have the opportunity to tie up numerous licensing deals with various pharmaceutical Companies, enabling ongoing huge revenue streams.
‘Nuvec’ has been years in development and with each trial the potential grows.
Yes good news - I was going to average down but been bitten by too many AIM Life Science companies - hope N4P is solid.
Unexpected jump. we must have some information on the horizon
or it will drop as fast as it went up but still movement is positive for now